Novo Historical Financial Ratios

NVO Stock  USD 71.79  1.81  2.46%   
Novo Nordisk is lately reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 65.31 will help investors to properly organize and evaluate Novo Nordisk AS financial condition quickly.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

About Novo Financial Ratios Analysis

Novo Nordisk ASFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Novo Nordisk investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Novo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Novo Nordisk history.

Novo Nordisk Financial Ratios Chart

At this time, Novo Nordisk's PB Ratio is very stable compared to the past year. As of the 26th of March 2025, EV To Sales is likely to grow to 10.37, while Dividend Yield is likely to drop 0.02.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Novo Nordisk AS stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Novo Nordisk sales, a figure that is much harder to manipulate than other Novo Nordisk AS multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Novo Nordisk AS dividend as a percentage of Novo Nordisk stock price. Novo Nordisk AS dividend yield is a measure of Novo Nordisk stock productivity, which can be interpreted as interest rate earned on an Novo Nordisk investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.
Most ratios from Novo Nordisk's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Novo Nordisk AS current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
At this time, Novo Nordisk's PB Ratio is very stable compared to the past year. As of the 26th of March 2025, EV To Sales is likely to grow to 10.37, while Dividend Yield is likely to drop 0.02.
 2022 2023 2024 2025 (projected)
Dividend Yield0.01190.01020.01590.0154
Price To Sales Ratio12.0113.479.5710.05

Novo Nordisk fundamentals Correlations

-0.390.980.560.69-0.860.720.30.981.00.820.22-0.390.70.4-0.840.130.820.93-0.210.28-0.30.860.76-0.350.66
-0.39-0.29-0.17-0.230.55-0.20.0-0.29-0.39-0.190.52-0.27-0.180.280.03-0.1-0.14-0.450.810.67-0.2-0.54-0.24-0.220.38
0.98-0.290.520.64-0.810.690.281.00.980.810.35-0.450.670.45-0.850.110.830.9-0.110.36-0.330.810.74-0.360.74
0.56-0.170.520.48-0.430.540.290.520.570.62-0.1-0.570.490.61-0.420.530.440.31-0.080.250.160.470.510.180.22
0.69-0.230.640.48-0.660.980.840.640.720.94-0.21-0.090.990.16-0.810.530.860.53-0.190.020.240.850.92-0.020.49
-0.860.55-0.81-0.43-0.66-0.63-0.35-0.81-0.87-0.66-0.10.35-0.64-0.360.68-0.26-0.65-0.880.4-0.10.16-0.91-0.620.42-0.47
0.72-0.20.690.540.98-0.630.840.690.740.97-0.16-0.150.990.23-0.830.580.90.52-0.130.070.250.840.960.030.53
0.30.00.280.290.84-0.350.840.280.320.69-0.260.00.850.1-0.510.780.630.09-0.05-0.090.580.610.720.180.33
0.98-0.291.00.520.64-0.810.690.280.980.810.35-0.450.670.45-0.850.110.830.9-0.110.36-0.330.810.74-0.360.74
1.0-0.390.980.570.72-0.870.740.320.980.840.2-0.380.730.39-0.850.150.830.92-0.210.27-0.280.870.77-0.340.66
0.82-0.190.810.620.94-0.660.970.690.810.84-0.04-0.250.950.31-0.890.440.930.62-0.070.190.080.830.96-0.040.61
0.220.520.35-0.1-0.21-0.1-0.16-0.260.350.2-0.04-0.65-0.150.61-0.29-0.340.160.280.520.81-0.73-0.12-0.1-0.720.71
-0.39-0.27-0.45-0.57-0.090.35-0.150.0-0.45-0.38-0.25-0.65-0.13-0.990.38-0.2-0.28-0.29-0.26-0.770.39-0.14-0.150.44-0.56
0.7-0.180.670.490.99-0.640.990.850.670.730.95-0.15-0.130.21-0.830.560.890.52-0.120.070.250.850.94-0.020.54
0.40.280.450.610.16-0.360.230.10.450.390.310.61-0.990.21-0.410.290.320.270.270.75-0.310.190.21-0.40.57
-0.840.03-0.85-0.42-0.810.68-0.83-0.51-0.85-0.85-0.89-0.290.38-0.83-0.41-0.16-0.93-0.74-0.09-0.440.29-0.73-0.880.42-0.81
0.13-0.10.110.530.53-0.260.580.780.110.150.44-0.34-0.20.560.29-0.160.29-0.14-0.14-0.150.760.450.460.420.02
0.82-0.140.830.440.86-0.650.90.630.830.830.930.16-0.280.890.32-0.930.290.680.00.25-0.10.790.93-0.230.72
0.93-0.450.90.310.53-0.880.520.090.90.920.620.28-0.290.520.27-0.74-0.140.68-0.280.24-0.50.780.57-0.560.6
-0.210.81-0.11-0.08-0.190.4-0.13-0.05-0.11-0.21-0.070.52-0.26-0.120.27-0.09-0.140.0-0.280.61-0.28-0.43-0.1-0.270.42
0.280.670.360.250.02-0.10.07-0.090.360.270.190.81-0.770.070.75-0.44-0.150.250.240.61-0.63-0.060.06-0.620.75
-0.3-0.2-0.330.160.240.160.250.58-0.33-0.280.08-0.730.390.25-0.310.290.76-0.1-0.5-0.28-0.630.110.140.81-0.48
0.86-0.540.810.470.85-0.910.840.610.810.870.83-0.12-0.140.850.19-0.730.450.790.78-0.43-0.060.110.81-0.160.45
0.76-0.240.740.510.92-0.620.960.720.740.770.96-0.1-0.150.940.21-0.880.460.930.57-0.10.060.140.81-0.010.53
-0.35-0.22-0.360.18-0.020.420.030.18-0.36-0.34-0.04-0.720.44-0.02-0.40.420.42-0.23-0.56-0.27-0.620.81-0.16-0.01-0.63
0.660.380.740.220.49-0.470.530.330.740.660.610.71-0.560.540.57-0.810.020.720.60.420.75-0.480.450.53-0.63
Click cells to compare fundamentals

Novo Nordisk Account Relationship Matchups

Novo Nordisk fundamentals Accounts

202020212022202320242025 (projected)
Price To Sales Ratio7.8411.9912.0113.479.5710.05
Dividend Yield0.02020.01270.01190.01020.01590.0154
Ptb Ratio15.7223.8625.4529.3719.3820.34
Days Sales Outstanding92.54121.32118.61118.27109.8765.31
Book Value Per Share13.5715.418.4323.7732.2233.83
Free Cash Flow Yield0.030.02820.03020.02240.02510.0329
Operating Cash Flow Per Share11.1311.9717.4124.2927.1628.52
Stock Based Compensation To Revenue0.0064830.0073860.0086970.0092530.0078820.00427
Capex To Depreciation3.841.232.04.136.06.3
Pb Ratio15.7223.8625.4529.3719.3820.34
Ev To Sales7.8212.112.0813.539.8710.37
Free Cash Flow Per Share6.410.3714.1615.6215.6416.42
Roic0.620.520.440.490.540.22
Inventory Turnover1.131.211.171.121.091.69
Net Income Per Share9.0310.412.2618.6722.6723.81
Days Of Inventory On Hand323.22302.72312.91324.65334.89215.38
Payables Turnover3.662.671.831.41.541.47
Sales General And Administrative To Revenue0.03120.02880.02520.02090.01820.0173
Capex To Revenue0.0920.170.05250.08340.180.12
Cash Per Share2.733.815.26.745.916.2
Pocfratio19.1730.6926.9428.7322.9824.13
Interest Coverage138.7823.93197.91138.878.2674.34
Capex To Operating Cash Flow0.430.130.190.360.420.53
Pfcf Ratio33.3435.4533.1344.739.9141.91
Days Payables Outstanding99.69136.85199.99261.32236.49248.31
Ev To Operating Cash Flow19.1230.9827.128.8523.724.89
Pe Ratio23.6335.3538.2737.427.5328.91
Ev To Free Cash Flow33.2635.7933.3444.8841.1643.22
Earnings Yield0.04230.02830.02610.02670.03630.0345
Intangibles To Total Assets0.140.220.210.190.240.25
Net Debt To E B I T D A(0.041)0.250.170.110.630.67
Current Ratio0.940.860.890.820.740.7
Tangible Book Value Per Share9.146.07.0810.37.274.76
Receivables Turnover3.943.013.083.093.325.42
Graham Number52.4960.0371.2899.92128.2134.61

Pair Trading with Novo Nordisk

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.

Moving together with Novo Stock

  0.66CDIOW Cardio DiagnosticsPairCorr

Moving against Novo Stock

  0.5PLX Protalix BiotherapeuticsPairCorr
  0.48SNY Sanofi ADRPairCorr
  0.39GOSS Gossamer BioPairCorr
  0.36OCX OncoCyte CorpPairCorr
  0.31AZN AstraZeneca PLC ADRPairCorr
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.292
Dividend Share
11.4
Earnings Share
3.29
Revenue Per Share
65.202
Quarterly Revenue Growth
0.301
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.